CEO.CA's Inside the Boardroom: Kairos Pharma CEO on Phase 2 Safety Data, 165% Stock Move & September Efficacy Timeline
Kairos Pharma (NYSE:KAPA) CEO Dr. John Yu appeared on CEO.CA's 'Inside the Boardroom' to discuss significant clinical developments. The company reported promising safety data from their prostate cancer trial, demonstrating zero grade 3 or 4 toxicities, a notable improvement compared to standard treatments which show over 50% toxicity rates.
The interview highlighted upcoming efficacy data expected in September and potential expansion plans into lung cancer and other tumor types. The discussion was featured on CEO.CA, a leading investor social network platform for junior resource and venture stocks.
Kairos Pharma (NYSE:KAPA) Il CEO, Dr. John Yu, è apparso su 'Inside the Boardroom' di CEO.CA per discutere importanti sviluppi clinici. L'azienda ha riportato promettenti dati di sicurezza dal loro trial sul cancro alla prostata, evidenziando l'assenza di tossicità di grado 3 o 4, un miglioramento significativo rispetto ai trattamenti standard che mostrano tassi di tossicità superiori al 50%.
L'intervista ha messo in luce i prossimi dati di efficacia previsti per settembre e i potenziali piani di espansione verso il cancro ai polmoni e altri tipi di tumore. La discussione è stata trasmessa su CEO.CA, una piattaforma social leader per investitori focalizzata su azioni junior e venture.
Kairos Pharma (NYSE:KAPA) El CEO, Dr. John Yu, apareció en 'Inside the Boardroom' de CEO.CA para hablar sobre importantes avances clínicos. La compañía reportó prometedores datos de seguridad de su ensayo sobre cáncer de próstata, demostrando ausencia de toxicidades de grado 3 o 4, una mejora notable en comparación con los tratamientos estándar que presentan tasas de toxicidad superiores al 50%.
La entrevista destacó los próximos datos de eficacia esperados para septiembre y los posibles planes de expansión hacia el cáncer de pulmón y otros tipos de tumores. La charla fue presentada en CEO.CA, una plataforma social líder para inversores enfocada en acciones junior y de riesgo.
Kairos Pharma (NYSE:KAPA)의 CEO 존 유 박사가 CEO.CA의 'Inside the Boardroom'에 출연하여 중요한 임상 개발 사항을 논의했습니다. 회사는 전립선암 임상 시험에서 유망한 안전성 데이터를 보고했으며, 3급 또는 4급 독성 반응이 전혀 없음을 보여 표준 치료법의 50% 이상의 독성률에 비해 크게 개선된 결과를 나타냈습니다.
인터뷰에서는 9월에 발표될 예정인 효능 데이터와 폐암 및 기타 종양 유형으로의 확장 가능성에 대해 강조했습니다. 이 논의는 주니어 자원 및 벤처 주식 투자자들을 위한 주요 소셜 네트워크 플랫폼인 CEO.CA에서 소개되었습니다.
Kairos Pharma (NYSE:KAPA) Le PDG, Dr John Yu, est intervenu dans l'émission 'Inside the Boardroom' de CEO.CA pour discuter d'importants développements cliniques. La société a rapporté des données de sécurité prometteuses issues de leur essai sur le cancer de la prostate, montrant une absence totale de toxicités de grade 3 ou 4, une amélioration notable par rapport aux traitements standards qui présentent des taux de toxicité supérieurs à 50 %.
L'entretien a mis en avant les prochaines données d'efficacité attendues en septembre ainsi que les plans potentiels d'expansion vers le cancer du poumon et d'autres types de tumeurs. La discussion a été diffusée sur CEO.CA, une plateforme sociale leader pour les investisseurs spécialisée dans les actions junior et les entreprises en démarrage.
Kairos Pharma (NYSE:KAPA) CEO Dr. John Yu trat in CEO.CA's 'Inside the Boardroom' auf, um bedeutende klinische Entwicklungen zu besprechen. Das Unternehmen berichtete vielversprechende Sicherheitsdaten aus ihrer Prostatakrebs-Studie, die keinerlei Toxizitäten der Grade 3 oder 4 zeigten – eine bemerkenswerte Verbesserung gegenüber Standardbehandlungen, bei denen die Toxizitätsrate über 50 % liegt.
Im Interview wurden die bevorstehenden Wirksamkeitsdaten, die im September erwartet werden, sowie mögliche Expansionspläne in Lungenkrebs und andere Tumorarten hervorgehoben. Die Diskussion wurde auf CEO.CA präsentiert, einer führenden sozialen Investorenplattform für Junior-Ressourcen- und Venture-Aktien.
- Zero grade 3 or 4 toxicities reported in prostate cancer trial, compared to over 50% with standard treatments
- Planned expansion into lung cancer and additional tumor types indicates growth potential
- Upcoming catalyst with efficacy data release in September
- Efficacy data not yet available, creating uncertainty around treatment effectiveness
- Multiple tumor type expansion plans may require significant additional resources
Toronto, Ontario--(Newsfile Corp. - July 28, 2025) - CEO.CA ("CEO.CA"), the leading investor social network in junior resource and venture stocks, shares exclusive updates with CEOs of junior mining explorers.
Founded in 2012, CEO.CA, a wholly owned subsidiary of EarthLabs, Inc., is one of the most popular free financial websites and apps in Canada and for investors globally - with industry leading audience engagement and mobile functionality. Millions of people visit CEO.CA each year to connect with investors from around the world, share knowledge and view impactful stories about stocks, commodities, and emerging companies.
Meet the Executive Shaping the Biotech Landscape
'Inside the Boardroom' is more than just an interview series - it's a chance to gain firsthand knowledge from industry leaders, understanding their vision, challenges, and strategy.
We caught up with Dr. John Yu, CEO of Kairos Pharma, Ltd. (NYSE American: KAPA) to discuss the company's safety data showing zero grade 3 or 4 toxicities (compared to over
Kairos Pharma
(NYSE American: KAPA)
Cannot view this video? Visit:
https://www.youtube.com/watch?v=qJy-Fa2mHi0
Tune in to 'Inside the Boardroom' each week and be part of the conversation that's shaping the business landscape. Visit CEO.CA or our YouTube page for hundreds more executive interviews from CEO.CA here.
Interested in showcasing your company on 'Inside the Boardroom'? Get in touch with our team at sales@ceo.ca for further details and opportunities.
About CEO.CA
The leading community for investors & traders in junior resource & venture stocks. CEO.CA is one of the most popular free financial websites and apps in Canada and for small-cap investors globally -- with industry leading audience engagement and mobile functionality. Since 2012, CEO.CA has brought millions of investors together from over 164 countries to discuss their portfolio holdings and find new investment opportunities. Download our App on iOS or Android marketplace or visit us today at CEO.CA to set up your free account.
CEO.CA is a wholly owned subsidiary of EarthLabs, Inc.
For further information please contact:
CEO.CA
Email: hello@ceo.ca
Website: CEO.CA
Neither the TSX Venture Exchange ("TSXV"), OTC Best Market "(OTCQX") nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement
The information regarding any issuer contained or referred to in any interviews conducted by CEO.CA has been furnished by such issuer directly, and neither CEO.CA nor any of its affiliates or principals assumes any responsibility for the accuracy or completeness of such information or for any failure by an issuer to ensure disclosure of events or facts which may affect the significance or accuracy of any such information.
No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. This news release contains forward-looking information which involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward-looking information in this news release may include, but is not limited to, the objectives, goals, future plans, statements regarding exploration results and exploration and/or development plans of companies featured on the CEO.CA platform. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, capital and operating costs varying significantly from estimates, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, fluctuations in commodity prices, delays in the development of projects, currency risk and the other risks involved in the applicable exploration and development industry, and those risks set out in the public documents of such companies filed on SEDAR or elsewhere from time to time. Undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. CEO.CA disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/260333
FAQ
What safety results did Kairos Pharma (KAPA) report for its prostate cancer trial?
When will Kairos Pharma (KAPA) release efficacy data for its cancer treatment?
What are Kairos Pharma's (KAPA) expansion plans for its cancer treatment?
Who is the CEO of Kairos Pharma (KAPA)?
What makes Kairos Pharma's (KAPA) cancer treatment safety profile significant?
